Petrelintide record · updated 19h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only

All 3 studies Jump to the evidence Compare

What is Petrelintide used for?

Petrelintide is a synthetic peptide that acts as an analogue of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. Its mechanism of action involves binding to the amylin receptors in the brain and peripheral tissues, which leads to a reduction in appetite, slowing of gastric emptying, and modulation of glucose metabolism. These actions collectively contribute to weight loss and improved metabolic outcomes in individuals with obesity.

Primarily researched for · Metabolic & appetite

Development stage

where Petrelintide sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Cleared
Phase 1
Safety in humans
3Current
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity

NamePetrelintide

Chain length—

Molecular weight4,192 Da

FormulaC185H305N49O61

Structure typeNot established

ClassMetabolic

Research levelModerate Research

Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 172915807. No verified residue count for this compound.

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 21, 2026. How this works →

Research stats

Total studies3

Human / animal / cellular2 / 0 / 0

Highest trial phasePhase 2

Years covered2026

Latest study6d ago

Publication history

20262026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 3 Semantic Scholar UniProt

Study register

3 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial. TakeawayNot reported in abstract.	Human	2026	Title only0.10
Petrelintide and the evolving role of amylin agonism in obesity. TakeawayNot reported in abstract.	review	2026	Title only0.10
Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Finding-9.8% bodyweight change at 28 weeks with petrelintide 5.0 mg vs -1.7% with placebo.	Human	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Petrelintide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Petrelintide is discussed should be drawn from it.